Catalent shares rose after the company said at the J.P. Morgan Healthcare Conference that it expects revenue from manufacturing of GLP-1 drugs to be less than $100 million for the fiscal year 2024.
GLP-1 agonists, like Novo Nordisk's Ozempic and Eli Lilly's Zepbound are medications that help lower blood sugar levels and promote weight loss.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.